Equities Analysts Issue Forecasts for RARE Q3 Earnings

Key Points

• Wedbush analysts have downgraded Ultragenyx Pharmaceutical's Q3 2025 earnings per share estimate from ($1.00) to ($1.36), while maintaining a "Neutral" rating and a price target of $34.00.
• Ultragenyx reported earnings of ($1.17) per share for the most recent quarter, surpassing expectations, and achieved a revenue of $166.50 million, which is a 13.2% increase year-over-year.
• Despite a negative return on equity of 237.48% and various analysts lowering their price targets, the company's stock currently holds a consensus rating of "Moderate Buy" with an average target price of $81.50.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Analysts at Wedbush reduced their Q3 2025 earnings per share estimates for Ultragenyx Pharmaceutical in a report released on Wednesday, August 6th. Wedbush analyst L. Chico now expects that the biopharmaceutical company will post earnings per share of ($1.36) for the quarter, down from their previous estimate of ($1.00). Wedbush has a "Neutral" rating and a $34.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical's Q4 2025 earnings at ($1.42) EPS, FY2025 earnings at ($5.52) EPS, Q1 2026 earnings at ($1.22) EPS, Q2 2026 earnings at ($1.14) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($1.01) EPS, FY2026 earnings at ($4.44) EPS and FY2027 earnings at ($3.08) EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%. The business had revenue of $166.50 million for the quarter, compared to analysts' expectations of $161.37 million. During the same period last year, the firm posted ($1.52) earnings per share. The business's revenue for the quarter was up 13.2% on a year-over-year basis.

A number of other research firms have also recently weighed in on RARE. Cantor Fitzgerald lowered their price objective on Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 6th. Wells Fargo & Company lowered their price objective on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating on the stock in a research report on Thursday, July 10th. Canaccord Genuity Group lowered their price objective on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a research report on Friday. HC Wainwright raised Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 target price on the stock in a research note on Monday, July 28th. Finally, William Blair initiated coverage on Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They set an "outperform" rating and a $65.00 target price on the stock. One analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $81.50.

Ultragenyx Pharmaceutical Stock Down 1.0%

RARE stock opened at $27.54 on Monday. Ultragenyx Pharmaceutical has a twelve month low of $25.81 and a twelve month high of $60.37. The stock has a market cap of $2.65 billion, a P/E ratio of -4.98 and a beta of 0.25. The business's 50-day moving average price is $33.32 and its 200-day moving average price is $36.68.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the sale, the director owned 15,344 shares of the company's stock, valued at $573,712.16. The trade was a 13.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 5.50% of the stock is currently owned by insiders.

Institutional Trading of Ultragenyx Pharmaceutical

A number of large investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its stake in Ultragenyx Pharmaceutical by 28.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,218,942 shares of the biopharmaceutical company's stock worth $116,559,000 after acquiring an additional 706,519 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its position in shares of Ultragenyx Pharmaceutical by 81.6% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company's stock valued at $77,815,000 after purchasing an additional 965,919 shares during the last quarter. Federated Hermes Inc. increased its position in shares of Ultragenyx Pharmaceutical by 0.3% during the 1st quarter. Federated Hermes Inc. now owns 2,055,200 shares of the biopharmaceutical company's stock valued at $74,419,000 after purchasing an additional 5,400 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Ultragenyx Pharmaceutical by 4.0% during the 2nd quarter. Geode Capital Management LLC now owns 1,712,931 shares of the biopharmaceutical company's stock valued at $62,291,000 after purchasing an additional 66,394 shares during the last quarter. Finally, Deutsche Bank AG increased its position in shares of Ultragenyx Pharmaceutical by 0.5% during the 1st quarter. Deutsche Bank AG now owns 1,701,493 shares of the biopharmaceutical company's stock valued at $61,611,000 after purchasing an additional 8,385 shares during the last quarter. Institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.